Biosearch Technologies today announces that the company has expanded its licenses from Roche Molecular Systems, Inc. (Roche). The expanded license grants Biosearch the right to manufacture and sell validated kits to the in-vitro diagnostic (IVD) marketingplace as licensed products convered by multiple patents assigned to Roche.
The BiosearchTech Blog
Biosearch Technologies recently launched a video, Making of the Swine Flu Test Kit - Inside Biosearch Technologies, which had debuted last week at qPCR Symposium 2009 held in Millbrae, California. This video is an accurate re-enactment of Biosearch Technologies' rapid production of the H1N1 (Swine Flu) test kit that was developed by the Centers for Disease Control and Prevention (CDC).
Biosearch Technologies announced today that the company has licensed from the CDC the novel H1N1 Influenza signatures along with the Influenza A sub-typing panel signatures. This licensing agreement with the CDC makes Biosearch Technologies the first oligo manufacturer to have the right to manufacture and sell dual-labeled probes and primers bearing the H1N1 and Influenza A sub-typing signatures.
Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. for the right to make, have made, use and sell Micronics' products that incorporate Biosearch's proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics' infectious disease tests for sale in underdeveloped countries.
Biosearch Technologies has been selected for two Small Business Innovative Research (SBIR) grants from the Department of Defense (DoD). Both Phase 1 grants calls for the development of highly sensitive analyte specific reagents (ASRs) for a total of twelve pathogens. The ASRs are qPCR based, but modified for field deployment. Both grants include the following target pathogens: Dengue, Rift Valley Fever, Sand Fly Fever, Crimean-Congo Hemorrhagic Fever, Tick-Borne Encephalitis, Chikungunya, causative agents of typhus, spotted fever, anaplasmosis, Ehrlichioses, and Q fever. If Phase I turns out to be a success, Biosearch expects this project to lead into a multiyear Phase II award.
The FDA has awarded Biosearch Technologies a five year contract for the development of multiplexed, fluorescent bead-based assays to determine bioterror and food safety pathogens. The assay will be conducted on a Luminex® xMap® platform. Throughout the contract, Biosearch will collaborate with scientists at Lawrence Livermore National Laboratories (LLNL) and the Luminex Corporation to develop assays for agents listed by the CDC and USDA. Initial target analytes include Bacillus anthracis, the causative agent of anthrax; Yersinia pestis, the causative agent of the plague; and Francisella tularensis, the causative agent of tularemia.